Relationship Between Antiplatelet Agent (Cilostazol) and Plasma Inflammatory Factor APP770
Dec 14th 2018
We are pleased to introduce a new publication with regard to the
relationship between the effects of the antiplatelet agent (Cilostazol) and plasma inflammatory factor APP770.
The research team led by Dr. Naoki Saji MD, PhD, vice head of the Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology - Japan, has revealed the following outcome in their pilot study.
In the study, 41 subjects who were admitted to a hospital due to subcortical small vessel infarction and administrated antiplatelet agents, were divided into 2 groups according the drug used (aspirin alone vs. aspirin with cilostazol), then it has been analyzed the relationship between the prognosis after the treatment and plasma inflammatory factors.
In the result, it was observed that plasma MMP-9 and high sensitive CRP were elevated in the subjects with progressive neurological deficit and plasma APP770 levels tend to become low in the group with cilostazol.
Our #27736 Human APP770 Assay Kit was used in the above study. This assay is for research use only, not for use in diagnostic procedures.